Reduced risk of type 2 diabetes : As a diabetes medication , semaglutide can also help to prevent or delay the onset of type 2 diabetes in individuals with obesity or prediabetes
Lown M, Fuller R, Lightowler H, Fraser A, Gallagher A, Stuart B, Byrne C, Lewith G
The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events
95% CI, 1.112.16), as shown in Figure 2
doi: 10.3389/fendo.2022.927859 Received 25 April 2022 Accepted 13 June 2022 Published 11 July 2022 Volume 13 - 2022 Edited by Johannes Wolfgang Dietrich, Ruhr University Bochum, Germany Reviewed by Daniel Quast, St